A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting